COYA · Coya Therapeutics, Inc.
Market Cap
$111.66M
Shares
23.46M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$7.95M
+123.6%
FY2025
Net Income
-$21.23M
-42.6%
FY2025
Operating Margin
-283.87%
+201.5pp
FY2025
Diluted EPS
-$1.27
-29.6%
FY2025
Operating Cash Flow
-$10.74M
-4.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $8.02M | $7.95M | $3.55M | $6M | $0 | — | |
| $16.98M | $16.73M | $11.87M | $5.5M | $4.41M | $2.54M | |
| $11.86M | $11.45M | $8.89M | $7.83M | $4.85M | $2.31M | |
| $31.17M | $30.5M | $20.8M | $13.91M | $9.81M | $4.87M | |
| -$23.15M | -$22.56M | -$17.25M | -$7.9M | -$9.81M | -$4.87M | |
| — | -283.87% | -485.35% | -131.67% | — | — | |
| $1.48M | $1.33M | $1.65M | $639.37K | $63.67K | -$21.48K | |
| — | -$21.22M | -$15.6M | -$7.26M | -$12.24M | — | |
| — | $3089 | -$720.29K | $723.85K | $0 | — | |
| -$21.67M | -$21.23M | -$14.88M | -$7.99M | -$12.24M | -$4.89M | |
| — | -267.14% | -418.7% | -133.08% | — | — | |
| USD/shares | -$1.07 | -$1.27 | -$0.98 | -$0.79 | -$4.73 | -$1.89 |
| USD/shares | -$1.07 | -$1.27 | -$0.98 | -$0.79 | -$4.73 | -$1.89 |
| shares | — | 16.73M | 15.24M | 10.16M | 2.59M | 2.59M |
| shares | — | 16.73M | 15.24M | 10.16M | 2.59M | 2.59M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.50×
EV/EBIT
—
Peer median 10.56×
P/E (TTM)
—
Peer median 7.58×
Peer medians compare against the 300 similar-size Biotechnology companies (of 516 listed).
Key facts
CIK
1835022
CUSIP
22407B108
13F (30d)
40 filings
40 filers
Visit website
Investor relations